Medtronic Executives to Speak at Upcoming Investor Conferences

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences, with its executives answering questions about the company:

10 ^th Annual SVB Leerink Global Healthcare Conference
Wednesday, February 24, 2021 , at 9:20 am EST
Speaker: Mike Weinstein , senior vice president of strategy

Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
Thursday, February 25, 2021 , at 2:25 pm EST
Speaker: Brett Wall , executive vice president & president, neuroscience portfolio

Cowen 41st Annual Health Care Conference
Tuesday, March 2, 2021 , at 12:50 pm EST
Speaker: Karen Parkhill , executive vice president & chief financial officer

Oppenheimer 31 ^st Annual Healthcare Conference
Tuesday, March 16, 2021 , at 1:10 pm EDT
Speaker: Sean Salmon , executive vice president & president, diabetes operating unit, cardiovascular portfolio

A live webcast for each session will be available on the date and time of each of the conferences noted above by clicking on the Investors Events link at https://investorrelations.medtronic.com . An archived audio file will be available for replay on the same webpage later in the day.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Erika Winkels	Ryan Weispfenning
Public Relations	Investor Relations
+1-763-526-8478	+1-763-505-4626

View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-executives-to-speak-at-upcoming-investor-conferences-301228653.html

SOURCE Medtronic plc

View original content to download multimedia: https://www.newswire.ca/en/releases/archive/February2021/17/c9961.html

News Provided by Canada Newswire via QuoteMedia

Medtronic MDT Medical Device Investing

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Date:	Thursday, May 2, 2024
Time:	8:00 a.m. U.S. EDT
Webcast:	http://ir.bauschhealth.com/events-and-presentations

Investor Contact:		Media Contact:
Garen Sarafian		Kevin Wiggins
ir@bauschhealth.com		corporate.communications@bauschhealth.com
(877) 281-6642 (toll-free)		(908) 541-3785

Investor Contact:		Media Contact:

Garen Sarafian		Kevin Wiggins
ir@bauschhealth.com		corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)		(848) 541-3785

Investor Contact:
Knight Therapeutics Inc.

Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T. +598.2626.2344
F: 514.481.4116
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

Contacts:
Sabrina Zimring	Ryan Weispfenning
Public Relations	Investor Relations
+1-720-774-3454	+1-763-505-4626

Medtronic Executives to Speak at Upcoming Investor Conferences

Latest News

Latest Press Releases

Related News

TOP STOCKS